AbbVie Inc. (ABBV) on Decifer

Decifer ranks ABBV number 258 of 277 tracked names on durable business quality.

Why it ranks here

• It earns solid returns on the money it puts to work, around 13% and it turns most of its profit into real cash.
• Revenue is growing about 9% a year, profits are expected to grow 17%, and growth is speeding up, not slowing down.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power.
• and has the balance sheet to fund its growth.
• It is not watering down its owners with new shares and it returns cash to shareholders.
• It trades about 397% above similar companies, and its growth does not yet back up that price.
• It grows revenue about 9% with profits expected to grow 17%, but it trades about 397% above similar companies without the growth to back that up and has no worldview role.

The current read

The evidence on ABBV lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Healthcare, Biotech & Devices: AbbVie Inc. sits in the large-cap pharma layer of the Healthcare, Biotech & Devices story.

Read the full ABBV research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.